← Oncology Approval Tracker

FDA DECISION ·

Nerlynx + capecitabine

neratinib + capecitabine · Puma Biotechnology

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with advanced or metastatic HER2-positive breast cancer after two or more HER2-directed regimens in the metastatic setting.

LAMPGEN ANALYSIS

Why it matters

Added an oral combination after several prior HER2-directed treatments.

What research teams should watch

Check prior metastatic regimens and provide a diarrhea prevention and escalation plan.

PRIMARY RECORDS

Sources